Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,140.87
(
0.52%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.65
(
2.39%
)
Bitcoin
74,767.53
(
-0.10%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

ciotera

Send PM Follow Ignore
Followers 8
Posts 512
Boards Moderated 0
Alias Born 08/03/2005

ciotera

Re: DewDiligence post# 150580

Monday, 10/15/2012 2:14:30 PM

Monday, October 15, 2012 2:14:30 PM

Post# of 257253

ABT’s HCV results ...




Agreed, but it's starting to look like efficacy is rapidly becoming a cost of entry in this space. If the other all-oral regimens (GILD, BMY) clear the 80-90% SVR hurdle but offer a much more tolerable (no ritonavir) and convenient (QD) option, ABT's regimen will not look very competitive.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now